Cognition Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Purchasenew Yorkthe Company Specializes In Discovering And Developing Small Molecule Therapeutics Aimed At Treating Age Related Degenerative Disorders Of The Central Nervous Systemcognition Therapeutics Is Publicly Traded On The Nasdaq Under The Ticker Symbol Cgtx And Employs Between 11 To 50 People The Company S Mission Focuses On Addressing Neurodegenerative Diseasesparticularly Alzheimer S Disease And Dementia With Lewy Bodiestheir Lead Product Candidatezervimesinect1812 Is An Oral Therapeutic Designed To Improve Cellular Functions Impaired In These Conditionszervimesine Targets The Sigma 2 Receptor Complex To Help Restore Processes Like Autophagy And Protein Traffickingpotentially Protecting Neurons From Damageadditionallycognition Therapeutics Is Exploring Zervimesine For Treating Dry Age Related Macular Degenerationthe Company Is Committed To Advancing Clinical Research To Develop Effective Treatment Options For These Challenging Disorders
